Prediction Held up AI assessment confidence: 90% certainty 3/5 debate potential 4/5

Lipman: Most lab-grown meat startups will fail to reach commercial scale

Ari Lipman · Microbes, meat and materials: biotech meets climatetech · Jan 18, 2022 · at 38:14

Venture capitalist Ari Lipman discusses the economic viability and scaling bottlenecks facing cultured meat startups with host Shayle Kann.

0:00 / 0:10exact quote · 10.4s

720p mp4 · rendered on demand · StarZero watermark

“I'm anticipating that the vast majority will not be able to reach commercial scale and not be able to reach the market, so we'll either see a bunch of consolidation or a bunch of dead companies in the wake of whatever reckoning may be coming.”

quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →

The claim, plainly

The vast majority of lab-grown meat startups active in early 2022 will fail to reach commercial scale and market distribution, resulting in widespread shutdowns or industry consolidation.

a quote alone can be ambiguous, so this restates it with the references and context of the conversation around it resolved. AI-written; the tape below the player is the source.

Assessment

As of September 2026, the prediction has proven accurate across both of its primary components. Following the peak of venture capital funding in 2021, the cultivated meat sector experienced a severe capital contraction, with annual funding falling by more than 85% by 2024–2025. Of the approximately 100 cultivated meat startups active globally in early 2022, the vast majority have failed to achieve commercial scale or regular market distribution. Even leading, heavily capitalized pioneers (such as Believer Meats, Meatable, SCiFi Foods, and New Age Eats) underwent insolvency and ceased operations, while others consolidated (e.g., Shiok Meats merging with Umami Bioworks, Vital Meat and Gourmey merging into Parima). The remaining active firms remain largely limited to pilot-scale R&D, hybrid B2B ingredients, or restricted boutique tastings, with global commercial volume remaining negligible.

Venture capital investment into cultivated meat collapsed from roughly $1 billion in 2021 to below $140 million in 2024 and ~$82.6 million in 2025.
Prominent venture-backed early-2022 startups shut down or entered liquidation due to high capex hurdles and lack of follow-on funding, including Believer Meats (raised >$390M), Meatable (raised >$95M), SCiFi Foods (raised ~$40M), and New Age Eats (raised >$32M).
Consolidations occurred across the sector (e.g., Shiok Meats acquired by Umami Bioworks in 2024; Vital Meat and Gourmey merging into Parima in 2025).
No active 2022 startup has achieved continuous large-scale commercial production and broad retail market distribution; leading survivors (e.g., UPSIDE Foods, GOOD Meat, Vow) paused commercial plant buildouts or remain restricted to limited foodservice tastings.

Checked against

[1] agfundernews.com [2] greenqueen.com.hk [3] naturetechmemos.com [4] naturetechmemos.com [5] wikipedia.org [6] gfi.org [7] cultivatedmeat.co.uk [8] agfundernews.com

lab grown meat startups shut down consolidated Good Food Institute "cultivated meat" startups status commercial scale 2025 2026 cultivated meat startups funding shutdowns 2024 2025 2026 "UPSIDE Foods" production scale retail restaurants 2025 2026 cultivated meat commercial scale market distribution status 2025 2026 Good Food Institute cultivated meat state of the industry report 2024 2025 "New Age Eats" shut down 2023 "SCiFi Foods" shut down 2024

assessed as of 2026-09-03

This assessment is an AI reading of a public statement, made against the cited references with the confidence shown. It can be wrong. The quote, the tape and the references are all on this page; if something is off, use report an error below. full disclaimer →

Mentioned

Ari Lipman lab-grown meat companies

⚑ Spot an error? Report it

More from Ari Lipman

Opinion

Lipman: Synbio cell engineering as software is mostly marketing

“Many of the sort of publics in bio companies or the leadings in bio companies will talk about their, you know, cell engineering platform as if it's a software platform. We're really not there yet. It's more marketing than anything else in my opinion at the mom…”

Ari Lipman Jan 18, 2022 ▶ 16:14 Microbes, meat and materials: biotech meets climatetech

Opinion

Lipman: Carbon-neutral products no longer strictly require price parity

“No, I think that's something that's changed in the environment is that you don't necessarily have to be at price parity. It seems like in some of these industries or some of these products to be successful. So It seems like consumers and, you know, certain …”

Ari Lipman Jan 18, 2022 ▶ 8:27 Microbes, meat and materials: biotech meets climatetech

Assertion Partly supported

Lipman: Downstream processing accounts for most industrial biomanufacturing costs

“Most of the cost actually comes in the downstream processing. So after you grow up these cells in these big steel tanks the vast majority of costs come after that phase where you have to process this wet biomass and spin it down and treat it and purify it.”

Ari Lipman Jan 18, 2022 ▶ 14:19 Microbes, meat and materials: biotech meets climatetech

Prediction Not checkable as stated

Lipman: Animal agriculture is never going to completely disappear

“And I don't think animal agriculture is ever going to go away.”

Ari Lipman Jan 18, 2022 ▶ 20:52 Microbes, meat and materials: biotech meets climatetech

Prediction Not checkable as stated

Lipman: Cultured meat will not achieve an affordable price point at scale

“Technically they may be able to, but I don't think that it will come out at any affordable price at the end of that scaling process.”

Ari Lipman Jan 18, 2022 ▶ 38:52 Microbes, meat and materials: biotech meets climatetech

Prediction Not checkable as stated

Lipman: Lab-grown meat will struggle to gain non-coastal consumer adoption

“And I think lab grown meat is all, is going to really struggle to you know, get consumers on board, especially not coastal consumers, not the ones on the blue coasts.”

Ari Lipman Jan 18, 2022 ▶ 38:59 Microbes, meat and materials: biotech meets climatetech

Lipman: Most lab-grown meat startups will fail to reach commercial scale

More from Ari Lipman

Turn any episode into a week of clips.